US6136814A
(en)
*
|
1997-12-08 |
2000-10-24 |
Fujisawa Usa, Inc. |
Aqueous acyclovir product
|
SE9801704D0
(sv)
*
|
1998-05-14 |
1998-05-14 |
Bioglan Ab |
Biologically active composition
|
SE9801705D0
(sv)
*
|
1998-05-14 |
1998-05-14 |
Bioglan Ab |
Biologically active composition
|
AU7604400A
(en)
*
|
1999-09-21 |
2001-04-24 |
Emory University |
Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
|
DE60028754T2
(de)
*
|
1999-11-12 |
2007-05-31 |
Abbott Laboratories, Abbott Park |
Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
JP4512700B2
(ja)
*
|
2003-06-02 |
2010-07-28 |
トーアエイヨー株式会社 |
アシクロビル含有水溶液製剤
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US20050101605A1
(en)
*
|
2003-11-07 |
2005-05-12 |
Ahmed Salah U. |
Oral liquid formulations of methotrexate
|
KR101228356B1
(ko)
|
2004-04-08 |
2013-02-05 |
바이오매트리카 인코포레이티드 |
생명과학용 시료 보관 및 시료 관리의 통합
|
ES2812250T3
(es)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
GB2432528B
(en)
*
|
2005-11-29 |
2011-04-06 |
Ian Ripley |
Anti-viral compositions comprising flavanone glycosides and fruit acids
|
NZ571819A
(en)
*
|
2006-03-08 |
2011-04-29 |
Nihon Nohyaku Co Ltd |
External pharmaceutical composition comprising luliconazole and either N-methyl-2-pyrrolidone, propylene carbonate or crotamiton
|
US8268876B2
(en)
*
|
2006-03-08 |
2012-09-18 |
Nihon Nohyaku Co., Ltd. |
Pharmaceutical composition for external use
|
US8058303B2
(en)
|
2006-03-08 |
2011-11-15 |
Nihon Nohyaku Co, Ltd |
Pharmaceutical composition for external use
|
MX2008015599A
(es)
*
|
2006-06-14 |
2009-03-06 |
Reddys Lab Ltd Dr |
Composiciones topicas.
|
HUE031334T2
(hu)
|
2006-09-22 |
2017-07-28 |
Pharmacyclics Llc |
Bruton-tirozinkináz inhibitorok
|
KR100721126B1
(ko)
|
2006-12-28 |
2007-05-23 |
(주)바이오앤에이치엔티 |
모기 기피제 조성물
|
EP2191826B1
(en)
*
|
2007-09-05 |
2017-03-08 |
Pola Pharma Inc. |
Pharmaceutical composition
|
PL2191828T3
(pl)
*
|
2007-09-05 |
2017-02-28 |
Pola Pharma Inc. |
Przeciwgrzybicza kompozycja farmaceutyczna
|
WO2009031643A1
(ja)
|
2007-09-05 |
2009-03-12 |
Pola Pharma Inc. |
抗真菌組成物
|
WO2009035818A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA2719358C
(en)
*
|
2008-03-31 |
2017-10-24 |
Altan Co., Ltd. |
Antiviral agent and antiviral composition
|
GB2460915B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
US7981925B2
(en)
|
2008-08-27 |
2011-07-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EA021943B1
(ru)
*
|
2009-01-09 |
2015-10-30 |
Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг |
Способ изготовления вагинального суппозитория
|
CA2752557A1
(en)
*
|
2009-02-13 |
2010-08-19 |
Topica Pharmaceuticals, Inc. |
Anti-fungal formulation
|
CN102387786B
(zh)
|
2009-04-09 |
2015-09-09 |
宝丽制药股份有限公司 |
抗真菌药物组合物
|
JP5688405B2
(ja)
|
2009-04-09 |
2015-03-25 |
株式会社ポーラファルマ |
抗真菌医薬組成物
|
KR101754697B1
(ko)
|
2009-08-25 |
2017-07-06 |
가부시키가이샤 폴라 파마 |
항진균성 약제학적 조성물
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
WO2011130689A1
(en)
|
2010-04-15 |
2011-10-20 |
Tracon Pharmaceuticals, Inc. |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
HUE029570T2
(en)
|
2010-04-27 |
2017-03-28 |
Calcimedica Inc |
Intracellular calcium modifying compounds
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CA2806670A1
(en)
|
2010-07-26 |
2012-02-09 |
Biomatrica, Inc. |
Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
|
EP2598661B1
(en)
|
2010-07-26 |
2017-09-27 |
Biomatrica, INC. |
Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
|
CA2809830C
(en)
|
2010-08-27 |
2019-09-10 |
Calcimedica, Inc. |
Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2934572A4
(en)
|
2012-12-20 |
2016-11-23 |
Biomatrica Inc |
FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US9382246B2
(en)
|
2013-12-05 |
2016-07-05 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
CA2938996A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Methods for the treatment of lung diseases with mast cell stabilizers
|
CA2938994A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Inhalable formulations of sodium cromolyn with improved bioavailability
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
EP3154338B1
(en)
|
2014-06-10 |
2020-01-29 |
Biomatrica, INC. |
Stabilization of thrombocytes at ambient temperatures
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20180244631A1
(en)
|
2015-02-27 |
2018-08-30 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
KR20230145258A
(ko)
|
2015-12-08 |
2023-10-17 |
바이오매트리카 인코포레이티드 |
적혈구 침강 속도의 감소
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
JP2019516700A
(ja)
|
2016-05-12 |
2019-06-20 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Ash1l阻害剤及びそれを用いた治療方法
|
CA3025268A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
MX2019002259A
(es)
|
2016-08-26 |
2019-09-18 |
Curtana Pharmaceuticals Inc |
Inhibicion de la actividad de la olig2.
|
JP2019528320A
(ja)
|
2016-08-31 |
2019-10-10 |
レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh |
特発性肺線維症による慢性咳の治療のためのクロモリン組成物
|
JP2019531308A
(ja)
|
2016-10-07 |
2019-10-31 |
レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh |
肺線維症の治療のためのクロモリン組成物
|
EP3706867A4
(en)
|
2017-11-07 |
2021-08-11 |
The Regents Of The University Of Michigan |
THERAPEUTIC COMBINATION FOR TREATMENT OF CEREBELLIC ATAXIA
|
JP7424637B2
(ja)
|
2017-11-10 |
2024-01-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Ash1l分解剤及びそれを用いた治療方法
|
JP7414282B2
(ja)
|
2017-12-07 |
2024-01-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Nsdファミリー阻害物質及びそれによる治療の方法
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
CN112533581A
(zh)
|
2018-06-07 |
2021-03-19 |
密歇根大学董事会 |
Prc1抑制剂及用其进行治疗的方法
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
WO2020044114A2
(en)
|
2018-08-29 |
2020-03-05 |
Ftf Pharma Private Limited |
Methotrexate pharmaceutical composition
|
US20200069742A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
WO2020085904A2
(en)
|
2018-10-24 |
2020-04-30 |
SeraNovo B.V. |
Deep eutectic solvent platform for oral pharmaceutical formulations
|
NL2021864B1
(en)
*
|
2018-10-24 |
2020-05-13 |
Seranovo B V |
Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
|
US10925904B2
(en)
|
2018-11-06 |
2021-02-23 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
JP2022516057A
(ja)
|
2018-12-31 |
2022-02-24 |
バイオメア フュージョン,エルエルシー |
メニン-mll相互作用の不可逆的阻害剤
|
WO2020160113A1
(en)
|
2019-02-01 |
2020-08-06 |
Myos Rens Technology Inc. |
Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
|
KR20220009373A
(ko)
|
2019-03-15 |
2022-01-24 |
유니사이시브 테라퓨틱스 인코포레이티드 |
니코란딜 유도체
|
CA3185209A1
(en)
|
2020-07-10 |
2021-01-27 |
Alyssa WINKLER |
Gas41 inhibitors and methods of use thereof
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
TW202320796A
(zh)
|
2021-08-11 |
2023-06-01 |
美商拜歐米富士恩股份有限公司 |
用於糖尿病的menin-mll相互作用之共價抑制劑
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|